Nifty
Sensex
:
:
11419.25
38337.01
-177.65 (-1.53%)
-560.45 (-1.44%)

Pharmaceuticals & Drugs

Rating :
50/99  (View)

BSE: 532321 | NSE: CADILAHC

228.40
-2.75 (-1.19%)
19-Jul-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  234.70
  •  235.55
  •  227.30
  •  231.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1479637
  •  3379.49
  •  432.50
  •  222.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 23,648.45
  • 12.79
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 30,637.50
  • 1.53%
  • 2.28

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.79%
  • 1.82%
  • 5.95%
  • FII
  • DII
  • Others
  • 3.93%
  • 7.80%
  • 5.71%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.57
  • 8.76
  • 11.98

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.89
  • 11.09
  • 9.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.54
  • 9.43
  • 7.42

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.03
  • 26.75
  • 25.32

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.00
  • 6.21
  • 5.33

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.34
  • 18.20
  • 17.73

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
3,732.80
3,250.20
14.85%
3,577.90
3,259.90
9.75%
2,961.20
3,221.90
-8.09%
2,893.70
2,234.80
29.48%
Expenses
2,932.40
2,379.80
23.22%
2,738.00
2,401.30
14.02%
2,273.40
2,364.80
-3.87%
2,248.70
1,958.10
14.84%
EBITDA
800.40
870.40
-8.04%
839.90
858.60
-2.18%
687.80
857.10
-19.75%
645.00
276.70
133.10%
EBIDTM
21.44%
26.78%
23.47%
26.34%
23.23%
26.60%
22.29%
12.38%
Other Income
38.40
28.70
33.80%
31.00
25.70
20.62%
30.40
22.50
35.11%
101.30
21.00
382.38%
Interest
77.30
15.40
401.95%
45.50
13.40
239.55%
35.70
40.50
-11.85%
35.00
21.80
60.55%
Depreciation
155.60
144.00
8.06%
153.70
146.90
4.63%
147.50
126.30
16.79%
141.80
121.60
16.61%
PBT
605.90
739.70
-18.09%
671.70
724.00
-7.22%
535.00
712.80
-24.94%
569.50
154.30
269.09%
Tax
126.70
144.20
-12.14%
158.60
178.60
-11.20%
124.70
212.30
-41.26%
120.30
29.30
310.58%
PAT
479.20
595.50
-19.53%
513.10
545.40
-5.92%
410.30
500.50
-18.02%
449.20
125.00
259.36%
PATM
12.84%
18.32%
14.34%
16.73%
13.86%
15.53%
15.52%
5.59%
EPS
4.49
5.77
-22.18%
4.99
5.31
-6.03%
4.08
4.92
-17.07%
4.50
1.35
233.33%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
-
13,165.60
11,904.90
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
4,630.60
3,686.80
Net Sales Growth
-
10.59%
26.97%
-0.53%
8.96%
19.76%
13.63%
20.79%
13.66%
25.60%
 
Cost Of Goods Sold
-
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
1,286.20
1,011.20
Gross Profit
-
9,024.30
8,248.00
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
3,344.40
2,675.60
GP Margin
-
68.54%
69.28%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
72.22%
72.57%
Total Expenditure
-
10,197.60
9,076.30
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
3,614.10
2,878.20
Power & Fuel Cost
-
247.20
226.30
174.50
168.80
145.40
129.70
124.40
93.40
78.90
66.00
% Of Sales
-
1.88%
1.90%
1.86%
1.79%
1.68%
1.80%
1.96%
1.77%
1.70%
1.79%
Employee Cost
-
2,099.40
1,820.30
1,485.20
1,261.60
1,096.50
974.00
818.40
679.90
584.00
401.10
% Of Sales
-
15.95%
15.29%
15.84%
13.38%
12.67%
13.48%
12.87%
12.92%
12.61%
10.88%
Manufacturing Exp.
-
1,334.70
1,197.50
955.30
1,019.60
1,136.90
936.50
897.30
718.90
553.40
429.10
% Of Sales
-
10.14%
10.06%
10.19%
10.82%
13.14%
12.96%
14.11%
13.66%
11.95%
11.64%
General & Admin Exp.
-
589.10
509.50
466.00
432.70
326.80
365.70
342.20
271.90
234.90
218.50
% Of Sales
-
4.47%
4.28%
4.97%
4.59%
3.78%
5.06%
5.38%
5.17%
5.07%
5.93%
Selling & Distn. Exp.
-
1,035.40
1,014.50
826.40
979.60
960.30
902.40
857.50
767.40
710.70
585.30
% Of Sales
-
7.86%
8.52%
8.81%
10.39%
11.10%
12.49%
13.49%
14.58%
15.35%
15.88%
Miscellaneous Exp.
-
750.50
651.30
502.60
561.80
417.40
310.30
157.40
185.90
166.00
585.30
% Of Sales
-
5.70%
5.47%
5.36%
5.96%
4.82%
4.30%
2.48%
3.53%
3.58%
4.53%
EBITDA
-
2,968.00
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
1,016.50
808.60
EBITDA Margin
-
22.54%
23.76%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
21.95%
21.93%
Other Income
-
206.20
133.00
147.10
116.60
57.20
58.00
38.40
53.00
22.80
15.90
Interest
-
193.50
110.80
63.10
52.80
67.90
90.20
168.70
182.70
69.90
82.10
Depreciation
-
598.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
126.90
133.90
PBT
-
2,382.10
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
842.50
608.50
Tax
-
530.30
564.40
128.90
177.40
259.40
106.00
118.80
113.00
106.40
74.10
Tax Rate
-
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
12.63%
12.27%
PAT
-
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
711.00
506.00
PAT before Minority Interest
-
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
736.10
529.80
Minority Interest
-
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
-25.10
-23.80
PAT Margin
-
13.69%
14.39%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
15.35%
13.72%
PAT Growth
-
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
-8.21%
40.51%
 
Unadjusted EPS
-
18.06
17.35
14.53
19.19
11.24
39.25
31.92
31.87
34.73
24.67

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
2,171.50
1,628.50
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
68.20
Total Reserves
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
2,069.10
1,560.30
Non-Current Liabilities
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
956.30
1,204.60
Secured Loans
1,578.00
200.60
319.60
393.80
664.00
851.40
917.20
901.90
670.90
978.20
Unsecured Loans
2,371.70
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
92.00
112.30
Long Term Provisions
184.10
155.90
151.20
120.70
90.40
76.10
66.50
75.60
61.90
0.00
Current Liabilities
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
1,415.90
871.10
Trade Payables
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
570.60
619.60
Other Current Liabilities
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
367.30
56.40
Short Term Borrowings
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
259.80
0.00
Short Term Provisions
189.40
152.20
68.90
81.30
382.50
292.70
247.30
228.10
218.20
195.10
Total Liabilities
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40
Net Block
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
1,832.60
1,684.40
Gross Block
15,702.30
9,338.50
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
2,801.70
2,557.80
Accumulated Depreciation
3,538.60
2,842.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
929.90
835.00
Non Current Assets
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
2,485.30
1,953.30
Capital Work in Progress
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
431.00
211.10
Non Current Investment
443.60
470.90
385.70
217.10
33.20
22.20
21.20
21.20
20.70
20.70
Long Term Loans & Adv.
410.40
300.00
384.70
661.20
637.10
511.10
400.10
247.80
201.00
0.00
Other Non Current Assets
159.80
130.30
234.10
174.70
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
2,125.30
1,779.90
Current Investments
229.90
274.80
49.10
199.10
121.20
64.40
93.30
3.00
0.00
0.00
Inventories
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
811.90
750.40
Sundry Debtors
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
765.20
466.80
Cash & Bank
649.30
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
295.20
250.70
Other Current Assets
980.10
318.30
80.00
124.10
311.50
323.50
345.90
332.00
253.00
312.00
Short Term Loans & Adv.
584.50
730.10
268.50
234.80
240.80
254.90
279.00
274.60
206.20
308.00
Net Current Assets
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
709.40
908.80
Total Assets
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
2,882.30
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
682.60
695.40
PBT
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
842.50
603.90
Adjustment
664.30
624.30
333.70
249.80
344.50
269.00
315.90
320.90
208.40
228.10
Changes in Working Capital
637.80
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
-175.30
-123.60
Cash after chg. in Working capital
3,684.20
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
875.60
708.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-675.40
-620.60
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
-152.50
-77.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
-126.50
-12.50
14.90
-80.70
-32.50
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5,738.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
-466.00
-371.60
Net Fixed Assets
-569.90
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
-266.60
-223.80
Net Investments
-1,106.80
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
-99.90
-3.50
Others
-4,062.00
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
-99.50
-144.30
Cash from Financing Activity
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
-172.10
-324.80
Net Cash Inflow / Outflow
-971.80
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
44.50
-1.00
Opening Cash & Equivalents
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
250.70
251.70
Closing Cash & Equivalent
879.20
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60
295.20
250.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
101.43
85.40
67.97
55.66
41.52
33.58
28.75
25.25
21.21
15.82
ROA
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
17.62%
14.94%
ROE
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
38.85%
37.71%
ROCE
15.88%
18.41%
16.50%
28.60%
23.21%
17.20%
18.21%
24.01%
30.56%
26.55%
Fixed Asset Turnover
1.05
1.37
1.38
1.76
1.80
1.63
1.55
1.58
1.75
1.54
Receivable days
99.21
83.84
76.72
63.29
56.38
51.71
52.78
57.47
47.97
45.13
Inventory Days
70.33
64.05
59.88
54.52
60.13
63.89
64.82
64.85
60.83
66.19
Payable days
72.33
71.22
74.18
67.53
55.78
50.51
43.54
49.87
64.40
75.83
Cash Conversion Cycle
97.21
76.67
62.42
50.28
60.73
65.09
74.05
72.45
44.40
35.49
Total Debt/Equity
0.76
0.62
0.75
0.43
0.62
0.79
0.99
0.89
0.50
0.67
Interest Cover
13.31
21.87
26.55
40.75
22.29
11.45
5.79
5.35
13.05
8.36

News Update


  • Zydus Cadila’s arm gets USFDA’s nod for Dextroamphetamine Saccharate
    19th Jul 2019, 14:46 PM

    The company has also received approval for Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate

    Read More
  • Zydus Cadila completes enrollment in Evidences III of Saroglitazar Magnesium
    18th Jul 2019, 11:47 AM

    Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico

    Read More
  • Zydus Cadila gets USFDA’s nod for Misoprostol Tablets
    3rd Jul 2019, 14:12 PM

    The drug will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila completes enrolment in Evidences IV phase 2 clinical trial of Saroglitazar Magnesium
    17th Jun 2019, 14:49 PM

    The trial will evaluate the percentage change from baseline in serum ALT levels in patients treated with Saroglitazar Magnesium as compared to placebo as the primary endpoint

    Read More
  • Cadila Healthcare’s receives EIR for its formulations manufacturing facility
    17th Jun 2019, 14:13 PM

    The EIR report has stated that the classification of the facility is 'Voluntary Action Indicated'

    Read More
  • Zydus’ Nesher Pharmaceuticals gets final nod for Omega-3-Acid Ethyl Esters Capsules
    17th Jun 2019, 11:42 AM

    Omega-3 acid ethyl esters, a type of fat found in fish oil, is used along with diet and exercise to help lower levels of a certain blood fat (triglyceride)

    Read More
  • Cadila Healthcare’s arm receives EIR for manufacturing facility in Ahmedabad
    15th Jun 2019, 11:28 AM

    The USFDA had conducted a PAI for Doxorubicin Liposomal, a complex oncological injectable at Alidac, the injectable onco manufacturing facility, from March 18 to March 26, 2019

    Read More
  • USFDA concludes inspection at Cadila Healthcare’s manufacturing facilities in St. Louis
    3rd Jun 2019, 15:30 PM

    The inspection concluded with 3 observations at one facility and 8 observations at the other facility of Nesher Pharmaceuticals with a recommendation for VAI

    Read More
  • Cadila Healthcare reports 22% fall in Q4 consolidated net profit
    29th May 2019, 14:38 PM

    The company has reported a standalone net profit of Rs 262.10 crore for the quarter ended March 31, 2019

    Read More
  • Zydus Cadila gets USFDA’s nod for Esomeprazole Magnesium Delayed-Release Capsules
    23rd May 2019, 11:03 AM

    It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Cadila Healthcare’s US arm among generic companies facing lawsuit by US states
    15th May 2019, 12:11 PM

    In Cadila Healthcare’s opinion this particular matter is not likely to have any material impact on the operations and financials of the company

    Read More
  • Zydus Cadila receives USFDA’s final approval for Chlorthalidone Tablets
    13th May 2019, 11:05 AM

    It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila’s arm recalls 7,668 bottles of Carvedilol Tablets from American market
    6th May 2019, 10:00 AM

    The drug firm is recalling the drug due to the ‘presence of foreign tablets/ capsules’

    Read More
  • USFDA concludes inspection at Cadila Healthcare’s manufacturing facility in Ahmedabad
    3rd May 2019, 16:06 PM

    The inspection was conducted from April 22, 2019 to May 3, 2019

    Read More
  • Zydus Cadila gets USFDA’s nod for Bosentan Tablets, Trientine Hydrochloride Capsules
    30th Apr 2019, 12:25 PM

    Both the products will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila, SIFI tie up to launch innovative intraocular lenses in India
    30th Apr 2019, 10:54 AM

    Zydus Cadila and SIFI look forward to bringing such innovations to India and to the entire South Asia region

    Read More
  • Zydus Cadila receives USFDA’s approval for Leflunomide Tablets
    25th Apr 2019, 14:07 PM

    This medication is used to treat rheumatoid arthritis, a condition affecting multiple small and large joints of the body

    Read More
  • Zydus Cadila receives approval from USFDA for Acetazolamide for Injection
    17th Apr 2019, 14:20 PM

    It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad

    Read More
  • Zydus Cadila starts phase 3 trial of Desidustat
    17th Apr 2019, 12:57 PM

    This Phase III study will be a multicenter (50- 60 sites), randomized, active-controlled clinical trial

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.